ConductScience.org, home

Comparison · NCT04733157-deaths

Study Group/Group A_(Tranexamic Acid) vs Control Group/Group B_(Placebo): deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Study Group/Group A_(Tranexamic Acid) vs Control Group/Group B_(Placebo): deaths from any cause. Trial comparisons, record NCT04733157-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04733157-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.00625wilson
Risk in group 200.0000000000000000004340.00623wilson
Risk difference, group 1 minus group 20-0.006230.00625newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Study Group/Group A_(Tranexamic Acid)The study group will receive TXA 1g intravenously at the onset of skin incision.~Tranexamic acid injection: Tranexamic 1g administered intravenously at the onset of skin incision at caesarean section0611EG000
Group 2Control Group/Group B_(Placebo)
There is an equivalent volume of normal saline for the control group.~Normal saline placebo: 10ml of normal saline will be administered intravenously at onset of skin incision at caesarean section to the placebo group
0613EG001

Harm

What it counts
Total, all-cause mortality
Time frame
1 week

Source ClinicalTrials.gov

Trial

Title
The Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Caesarean Section
NCT number
NCT04733157
Phases
PHASE3
Conditions
Postpartum Hemorrhage
Interventions
Tranexamic acid injection, Normal saline placebo
Lead sponsor
University of Zimbabwe
Results first posted
2023-03-20

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04733157-deaths